oxybutynin has been researched along with Melanoma in 2 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a worst-case scenario for consequences of repeated application on neoplastic growth, the melanin-binding drug, rasagiline, was used in a transdermal formulation applied directly to a human-derived melanoma to determine the effects on tumor growth." | 7.78 | Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. ( Arjmand, FM; Christianson, C; Dines, K; Hamlin, R; Huang, B; Meier-Davis, SR; Nagata, T; Shudo, J; Wen, J, 2012) |
| " As a worst-case scenario for consequences of repeated application on neoplastic growth, the melanin-binding drug, rasagiline, was used in a transdermal formulation applied directly to a human-derived melanoma to determine the effects on tumor growth." | 3.78 | Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. ( Arjmand, FM; Christianson, C; Dines, K; Hamlin, R; Huang, B; Meier-Davis, SR; Nagata, T; Shudo, J; Wen, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X | 1 |
| Li, H | 1 |
| Zhou, D | 1 |
| Chen, Z | 1 |
| Gu, Z | 1 |
| Meier-Davis, SR | 1 |
| Dines, K | 1 |
| Arjmand, FM | 1 |
| Hamlin, R | 1 |
| Huang, B | 1 |
| Wen, J | 1 |
| Christianson, C | 1 |
| Shudo, J | 1 |
| Nagata, T | 1 |
2 other studies available for oxybutynin and Melanoma
| Article | Year |
|---|---|
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Disease Models, Animal; Drug Delivery Systems; Extra | 2020 |
Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Ani | 2012 |